Hypera S.A. (OTCMKTS:HYPMY) Sees Significant Decrease in Short Interest

Hypera S.A. (OTCMKTS:HYPMY) was the recipient of a large decrease in short interest in March. As of March 15th, there was short interest totalling 100 shares, a decrease of 99.1% from the February 28th total of 11,300 shares. Based on an average daily volume of 15,800 shares, the short-interest ratio is currently 0.0 days. Approximately 0.0% of the company’s stock are sold short.

Hypera Stock Performance

Shares of Hypera stock opened at $3.51 on Friday. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.81 and a quick ratio of 1.41. The firm has a market cap of $2.22 billion, a price-to-earnings ratio of 8.78 and a beta of 0.99. The stock’s 50-day moving average is $3.31 and its 200-day moving average is $3.70. Hypera has a one year low of $2.64 and a one year high of $6.83.

Hypera (OTCMKTS:HYPMY) last issued its quarterly earnings results on Thursday, March 20th. The company reported $0.02 EPS for the quarter. The firm had revenue of $258.56 million for the quarter. Hypera had a net margin of 20.04% and a return on equity of 13.18%.

Hypera Company Profile

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.